Hospital
Main Line Hospitals, INC.
Main Line Hospitals, INC. was paid $17.19M by Medicaid between Aug 2019 and Dec 2024, across 187 billing codes. Its largest line is 99283, emergency room visit (moderate) — 39% of everything it billed.
33Billing provider infoMAIN LINE HOSPITALS, INC.
WYNNEWOOD, PA 19096
WYNNEWOOD, PA 19096
33aNPI1245335629assigned 09/13/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$17.19M
24GClaims253,729
24DCodes billed187
24AFirst – last monthAug 2019 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Pennsylvania
Rank by total paid#18 of 154
Median peer was paid$2.82M
This provider vs. median6.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,680 | $30K | |
| 2020 | 35,413 | $1.82M | |
| 2021 | 88,237 | $5.76M | |
| 2022 | 35,902 | $3.55M | |
| 2023 | 47,219 | $3.53M | |
| 2024incomplete | 45,278 | $2.50M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 39% | 30,101 | 29,068 | $6.68M |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 37% | 30,416 | 29,115 | $6.41M |
| G0378 | Hospital observation service, per hour | 4.7% | 623 | 589 | $805K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 2.0% | 1,493 | 1,447 | $336K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 1.7% | 3,172 | 2,755 | $291K |
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 1.5% | 9,037 | 6,384 | $264K |
| X0621 | 1.0% | 313 | 167 | $174K | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 1,735 | 1,410 | $155K |
| 64483 | <1% | 116 | 115 | $149K | |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | <1% | 871 | 826 | $114K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 715 | 700 | $106K |
| 96413 | Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance | <1% | 428 | 285 | $100K |
175 more codes
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | <1% | 424 | $94K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | <1% | 918 | $74K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 407 | $66K |
| 90750 | <1% | 196 | $59K | |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 6,316 | $58K |
| 76811 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation, detailed | <1% | 226 | $49K |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | <1% | 2,598 | $44K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 900 | $42K |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,929 | $41K |
| 76816 | Ultrasound, pregnant uterus, real time with image documentation, follow-up | <1% | 356 | $40K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 21,222 | $39K |
| 80053 | Comprehensive metabolic panel | <1% | 12,522 | $39K |
| 76830 | Ultrasound, transvaginal | <1% | 512 | $38K |
| 77066 | Tomosynthesis, mammo | <1% | 238 | $38K |
| J1050 | Injection, medroxyprogesterone acetate, 1 mg | <1% | 930 | $38K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 2,116 | $38K |
| 76815 | Ultrasound, pregnant uterus, real time with image documentation, limited | <1% | 528 | $32K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 445 | $31K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 711 | $28K |
| 76642 | <1% | 361 | $28K | |
| C8929 | Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography | <1% | 50 | $26K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 361 | $25K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 212 | $24K |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 372 | $24K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 1,286 | $22K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 2,340 | $22K |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 95 | $19K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,629 | $18K |
| 73564 | <1% | 562 | $18K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 3,495 | $16K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 846 | $16K |
| 77065 | Tomosynthesis, mammo | <1% | 130 | $15K |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 2,049 | $14K |
| 95810 | Polysomnography; sleep staging with 4 or more additional parameters | <1% | 30 | $14K |
| G0279 | Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) | <1% | 380 | $13K |
| 36591 | <1% | 335 | $13K | |
| 72110 | <1% | 246 | $13K | |
| 99213 | Doctor's office visit, returning patient (routine) | <1% | 174 | $12K |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 3,110 | $12K |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | <1% | 33 | $12K |
| 36415 | Collection of venous blood by venipuncture | <1% | 22,885 | $12K |
| 90715 | <1% | 953 | $11K | |
| 92014 | Ophthalmological services: medical examination and evaluation, comprehensive, established patient | <1% | 142 | $11K |
| 71250 | <1% | 126 | $10K | |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 632 | $10K |
| 96367 | <1% | 195 | $10K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 185 | $9K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 13 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 485 | $8K |
| 73610 | <1% | 327 | $8K | |
| 93971 | <1% | 158 | $8K | |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 333 | $8K |
| 86900 | <1% | 952 | $7K | |
| 71045 | Radiologic examination, chest; single view | <1% | 2,571 | $7K |
| 73030 | <1% | 322 | $7K | |
| 93017 | <1% | 77 | $7K | |
| 85027 | <1% | 1,032 | $7K | |
| 90686 | <1% | 1,248 | $7K | |
| 84484 | <1% | 3,822 | $7K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 146 | $7K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 3,768 | $6K |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 14 | $6K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 383 | $6K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | <1% | 331 | $6K |
| 92004 | Ophthalmological services: medical examination and evaluation, comprehensive, new patient | <1% | 41 | $5K |
| 93975 | <1% | 154 | $5K | |
| 76801 | <1% | 56 | $5K | |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 12 | $5K |
| 81001 | <1% | 5,861 | $5K | |
| 85610 | <1% | 1,231 | $5K | |
| 84703 | <1% | 891 | $4K | |
| 73630 | <1% | 264 | $4K | |
| 85730 | <1% | 765 | $4K | |
| 76813 | <1% | 35 | $4K | |
| 73502 | <1% | 198 | $4K | |
| 72100 | <1% | 196 | $4K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 26 | $4K |
| 87631 | <1% | 50 | $4K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 13 | $3K |
| 86850 | <1% | 733 | $3K | |
| 93351 | <1% | 13 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 601 | $3K |
| 76536 | <1% | 28 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,549 | $3K |
| 90732 | <1% | 106 | $3K | |
| 93970 | <1% | 27 | $3K | |
| C1769 | Guide wire | <1% | 287 | $3K |
| 83735 | <1% | 1,069 | $3K | |
| 81025 | <1% | 346 | $3K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 595 | $2K |
| 73130 | <1% | 152 | $2K | |
| 0134A | <1% | 45 | $2K | |
| G0008 | Administration of influenza virus vaccine | <1% | 130 | $2K |
| 77080 | <1% | 28 | $2K | |
| 87480 | <1% | 347 | $2K | |
| 72141 | <1% | 12 | $2K | |
| 87660 | <1% | 347 | $2K | |
| 86901 | <1% | 736 | $2K | |
| 84702 | <1% | 417 | $2K | |
| G0009 | Administration of pneumococcal vaccine | <1% | 76 | $2K |
| 83690 | <1% | 1,456 | $2K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 437 | $2K |
| J2704 | Injection, propofol, 10 mg | <1% | 3,644 | $2K |
| J2916 | Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg | <1% | 500 | $1K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 75 | $1K |
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | <1% | 35 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 127 | $1K |
| 73110 | <1% | 71 | $1K | |
| 80061 | Lipid panel | <1% | 204 | $1K |
| 72040 | <1% | 41 | $1K | |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 169 | $1K |
| 73590 | <1% | 41 | $1K | |
| 82248 | <1% | 229 | $1K | |
| 83880 | <1% | 231 | $975.10 | |
| 83605 | <1% | 567 | $927.44 | |
| 87510 | <1% | 346 | $910.02 | |
| 96376 | <1% | 250 | $905.73 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 262 | $830.73 |
| 87077 | <1% | 445 | $814.35 | |
| Q9957 | Injection, perflutren lipid microspheres, per ml | <1% | 176 | $734.63 |
| 85379 | <1% | 275 | $678.40 | |
| 76857 | <1% | 57 | $661.85 | |
| 81003 | <1% | 1,447 | $650.12 | |
| 87186 | <1% | 290 | $605.50 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 849 | $597.12 |
| 73560 | <1% | 27 | $472.60 | |
| 73552 | <1% | 13 | $446.35 | |
| 91322 | <1% | 16 | $412.47 | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 2,904 | $386.08 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 59 | $351.46 |
| 92015 | Determination of refractive state | <1% | 41 | $318.96 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,391 | $267.73 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 4,716 | $256.68 |
| 90480 | <1% | 16 | $247.00 | |
| 88342 | <1% | 16 | $243.50 | |
| 73080 | <1% | 14 | $225.08 | |
| 92134 | <1% | 12 | $221.99 | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 43 | $207.65 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 4,274 | $205.35 |
| 90662 | <1% | 18 | $198.49 | |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | <1% | 362 | $181.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 1,500 | $167.28 |
| J1815 | Injection, insulin, per 5 units | <1% | 148 | $151.80 |
| 82570 | <1% | 55 | $142.07 | |
| 82803 | <1% | 46 | $133.70 | |
| 90656 | <1% | 45 | $113.12 | |
| 82550 | <1% | 61 | $96.23 | |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 2,513 | $87.27 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 846 | $78.61 |
| 83615 | <1% | 14 | $72.22 | |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | <1% | 1,008 | $61.11 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 284 | $54.67 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 15 | $50.84 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 453 | $44.45 |
| 74018 | <1% | 12 | $39.79 | |
| J3475 | Injection, magnesium sulfate, per 500 mg | <1% | 328 | $36.08 |
| 87070 | <1% | 12 | $31.95 | |
| J2060 | Injection, lorazepam, 2 mg | <1% | 406 | $26.34 |
| 90472 | Immunization administration, each additional vaccine (list separately) | <1% | 148 | $24.39 |
| J3480 | Injection, potassium chloride, per 2 meq | <1% | 95 | $23.86 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,683 | $22.72 |
| 87205 | <1% | 12 | $20.84 | |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | 0% | 72 | $0.00 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 149 | $0.00 |
| J9271 | Injection, pembrolizumab, 1 mg | 0% | 81 | $0.00 |
| J1580 | Injection, garamycin, gentamicin, up to 80 mg | 0% | 13 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 34 | $0.00 |
| J1596 | Injection, glycopyrrolate, 0.1 mg | 0% | 104 | $0.00 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 0% | 76 | $0.00 |
| C1758 | Catheter, ureteral | 0% | 12 | $0.00 |
| J1630 | Injection, haloperidol, up to 5 mg | 0% | 56 | $0.00 |
| 0064A | 0% | 49 | $0.00 | |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 62 | $0.00 |
| J0500 | Injection, dicyclomine hcl, up to 20 mg | 0% | 28 | $0.00 |
| 90677 | 0% | 16 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialEHRLICH, LEIGH (EXEC VP / CHIEF FINANCIAL OFFICER)
| Provider | Location | Paid |
|---|---|---|
| Riddle Memorial Hospital | Media, PA | $4.78M |
| Main Line Hospitals, INC. | Bryn Mawr, PA | $4.52M |
| Main Line Hospitals, INC. | Paoli, PA | $2.60M |
| Main Line Hospitals, INC. | Wynnewood, PA | $368K |
| Main Line Hospitals, INC. | Malvern, PA | $272K |
| Main Line Hospitals, INC. | Broomall, PA | $18K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.